VeriMom¿Es rh-oligopeptide-1 seguro durante el embarazo?
No harmonised CLP classification (ECHA Annex VI) or SCCS/CIR reproductive safety restriction identified. However, as a peptide growth factor (EGF family) there is a theoretical class-based concern about mitogenic activity relevant to developing tissues; no animal or human reproductive toxicity data were identified to confirm hazard (sources searched: ECHA Annex VI, SCCS/CIR, PubMed, PubChem/CosIng, EWG). Topical systemic absorption for large peptides like rhEGF is expected to be negligible, so direct systemic exposure in pregnancy is unlikely.
Pregnancy-safe products containing rh-oligopeptide-1
Related ingredients
Frequently asked questions
- ¿Es rh-oligopeptide-1 seguro durante el embarazo?
- No harmonised CLP classification (ECHA Annex VI) or SCCS/CIR reproductive safety restriction identified. However, as a peptide growth factor (EGF family) there is a theoretical class-based concern about mitogenic activity relevant to developing tissues; no animal or human reproductive toxicity data were identified to confirm hazard (sources searched: ECHA Annex VI, SCCS/CIR, PubMed, PubChem/CosIng, EWG). Topical systemic absorption for large peptides like rhEGF is expected to be negligible, so direct systemic exposure in pregnancy is unlikely.
- ¿Es rh-oligopeptide-1 seguro durante la lactancia?
- Same rationale as pregnancy: theoretical concern from growth-factor activity if systemically absorbed, but no evidence of reproductive or lactation-specific toxicity or breast milk transfer. Large peptide size and available topical formulations suggest negligible systemic bioavailability after topical cosmetic use (sources: PubMed, PubChem, CosIng, EWG).
- ¿Es rh-oligopeptide-1 seguro para la piel del bebé?
- Hazard and mechanism scores unchanged (no infant-specific data showing reproductive/ developmental toxicity). Exposure score increased by +1 because infant skin has a less mature barrier and higher surface-area-to-weight ratio; if the peptide has any measurable percutaneous uptake the relative exposure in 0–3 yr olds would be higher. No studies demonstrating placental/breastmilk transfer or infant adverse outcomes were found (sources: PubMed, CosIng, PubChem, EWG).
- ¿Cómo puntúa VeriMom a rh-oligopeptide-1?
- VeriMom puntúa rh-oligopeptide-1 en 73/100 (riesgo bajo) según el estado EU CosIng, clasificaciones ECHA y estudios PubMed.
- ¿Cuáles son las alternativas seguras a rh-oligopeptide-1 en el embarazo?
- Consulta nuestra lista de alternativas seguras a rh-oligopeptide-1 según función similar y clasificación sin riesgos conocidos.
Comprueba cualquier etiqueta en 2 segundos
Descarga VeriMom gratis — escanea cualquier producto y ve la puntuación de seguridad en el embarazo al instante.
Aviso Médico
Esta información es solo para fines educativos y no constituye asesoramiento médico. Las puntuaciones de seguridad se basan en datos disponibles públicamente y pueden no reflejar todos los riesgos. Siempre consulte a su profesional de salud antes de usar cualquier producto durante el embarazo o la lactancia.